Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep;23(9):986-987.
doi: 10.1016/S1473-3099(23)00277-3. Epub 2023 May 19.

CS-2034 mRNA vaccine: a new option for COVID-19 infection?

Ruiqi Zhang  1 , Ivan Fan-Ngai Hung  2
Affiliations
Comment

CS-2034 mRNA vaccine: a new option for COVID-19 infection?

Ruiqi Zhang et al. Lancet Infect Dis. 2023 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

IF-NH receives honoraria from Pfizer, Merck, and Gilead for lectures. IF-NH has offered consultative advice on COVID-19 vaccines to Moderna, Fosun, Sinovac, and Sinopharm. IF-NH has offered consultative advice on anti-SARS-CoV-2 monoclonal antibody treatment to AstraZeneca. IF-NH has received support for attending meetings from AstraZeneca and Merck. RZ declares no competing interests.

Comment on

References

    1. Huang Z, Xu S, Liu J, et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 omicron BA. 2 variant infection, severe illness, and death. BMC Med. 2022;20:400. - PMC - PubMed
    1. Wu J-D, Li J-X, Liu J, et al. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(23)00199-8. published online May 19. - DOI - PubMed
    1. Pan Y, Wang L, Feng Z, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet. 2023;401:664–672. - PMC - PubMed
    1. Abukhalil AD, Shatat SS, Abushehadeh RR, Al-Shami N, Naseef HA, Rabba A. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. BMC Infect Dis. 2023;23:5. - PMC - PubMed
    1. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection—increasing community access to testing program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1526–1530. - PMC - PubMed

Substances